The EU Commission continues to pursue "gun jumping" merger control proceedings against two pharmaceutical companies on EU merger control referral thresholds (Grail / Illumina)

On 20 August 2021, the European Commission (the Commission ) said that it would investigate whether Illumina’s decision, made public on 18 August 2021, to acquire Grail pending the Commission’s review of that transaction under Regulation 139/2004 on the control of concentrations

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission continues to pursue "gun jumping" merger control proceedings against two pharmaceutical companies on EU merger control referral thresholds (Grail / Illumina), 19 July 2022, e-Competitions July 2022, Art. N° 107865

Visites 1421

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues